Impact of mechanical circulatory support on outcomes in Takotsubo syndrome complicated by cardiogenic shock: Insights from the RETAKO registry

Aitor Uribarri,Ravi Vazirani,Manuel Almendro Delia,Marco Tomasino,Clara Fernández-Cordón,Agustín Martín,Emilia Blanco-Ponce,Jorge Salamanca,Miguel Corbí-Pascual,Oscar Vedia,Albert Duran-Cambra,Víctor Manuel Becerra,Carmen Lluch-Requerey,Sergio Raposeiras-Roubin,Marta Guillén-Marzo,Javier Lopez-País,Alberto Pérez-Castellanos,Petra Sanz Mayordomo,Manuel Martínez-Sellés,Sofía Vila-Sanjuán,Eduard Ródenas-Alesina,Iván J. Núñez-Gil
DOI: https://doi.org/10.1016/j.ijcard.2024.132681
IF: 4.039
2024-10-26
International Journal of Cardiology
Abstract:Background Cardiogenic shock (CS) complicates Takotsubo syndrome (TTS), significantly affecting patient outcomes. Since avoiding catecholamines, particularly inotropic agents, is recommended in TTS, temporary mechanical circulatory support (MCS) shows promise as a bridge to recovery. However, there is no prospective data on its use in TTS. Methods Patients from the prospective nationwide RETAKO registry were included and divided based on the use and type of MCS. Results From a national TTS registry, 1591 consecutive patients were initially enrolled between 2003 and 2022. Of these, 322 patients (20.2 %) developed CS, and 31 (9.6 %) were treated with MCS [20 intra-aortic balloon pump (IABP) (64.5 %), 8 veno-arterial extracorporeal membrane oxygenation (25.8 %), and 3 Impella-CP (9.7 %)]. Compared to CS patients managed only with drugs, MCS recipients exhibited a more severe clinical profile, with worse ventricular function and more right ventricular involvement. Despite encountering more complications, such as major bleeding and atrial fibrillation, MCS did not significantly influence in-hospital mortality (19.4 % in the MCS group vs 13.1 % in the no MCS group, p = 0.33). After adjusting for other predictors of in-hospital mortality (invasive mechanical ventilation, inotropic-vasoactive score, age, and SCAI stage), MCS was not associated with higher mortality. Conclusion Approximately 10 % of TTS patients complicated by CS were treated with MCS. Despite their more severe CS, patients treated with MCS had similar in-hospital mortality rates as those treated only with drugs, suggesting a potential benefit of MCS in selected cases.
cardiac & cardiovascular systems
What problem does this paper attempt to address?